Cargando…

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

BACKGROUND: STARDUST is a phase 3b randomized controlled trial comparing two ustekinumab treatment strategies in patients with Crohn's disease (CD): treat‐to‐target (T2T) versus standard of care (SoC). OBJECTIVE: We investigated the effect of a T2T or SoC ustekinumab treatment strategy on healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panés, Julian, Vermeire, Séverine, D'Haens, Geert R., Danese, Silvio, Magro, Fernando, Nazar, Maciej, Le Bars, Manuela, Lahaye, Marjolein, Ni, Lioudmila, Bravatà, Ivana, Gaya, Daniel R., Peyrin‐Biroulet, Laurent, Dignass, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256988/ https://www.ncbi.nlm.nih.gov/pubmed/37139642 http://dx.doi.org/10.1002/ueg2.12384

Ejemplares similares

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
por: Wils, Pauline, et al.
Publicado: (2023)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
por: D'Amico, Ferdinando, et al.
Publicado: (2021)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
por: Bonsack, Olivier, et al.
Publicado: (2023)

Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study
por: Allocca, Mariangela, et al.
Publicado: (2022)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up
por: Lansdorp, Corine A., et al.
Publicado: (2022)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo
por: Massimino, Luca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qggd2j3igsje7tietn290l8m98